{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:29:03Z","timestamp":1776918543297,"version":"3.51.2"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872751"],"award-info":[{"award-number":["81872751"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872863"],"award-info":[{"award-number":["81872863"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005047","name":"Natural Science Foundation of Liaoning Province","doi-asserted-by":"publisher","award":["2019-MS-301"],"award-info":[{"award-number":["2019-MS-301"]}],"id":[{"id":"10.13039\/501100005047","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Disruptive Technology Innovation Guidance Fund of Shenyang Pharmaceutical University","award":["DFJJ2018201"],"award-info":[{"award-number":["DFJJ2018201"]}]},{"name":"Development Project of Ministry of Education Innovation Team","award":["IRT1073"],"award-info":[{"award-number":["IRT1073"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ejmech.2019.111904","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T12:10:38Z","timestamp":1574165438000},"page":"111904","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis"],"prefix":"10.1016","volume":"187","author":[{"given":"Nan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minglin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junlong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongrui","family":"Lei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangyue","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2019.111904_bib1","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.cmet.2013.06.016","article-title":"Fibrosis and adipose tissue dysfunction","volume":"18","author":"Sun","year":"2013","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2019.111904_bib2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tips.2014.01.003","article-title":"FibromiRs: translating molecular discoveries into new anti-fibrotic drugs","volume":"35","author":"Pottier","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2019.111904_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1755-5922.2010.00228.x","article-title":"Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-\u03b2","volume":"30","author":"Edgley","year":"2012","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.ejmech.2019.111904_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.matbio.2017.12.016","article-title":"Targeting TGF-\u03b2 signaling for the treatment of fibrosis","volume":"68\u201369","author":"Gy\u00f6rf","year":"2018","journal-title":"Matrix Biol."},{"key":"10.1016\/j.ejmech.2019.111904_bib5","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A\u00a0phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2019.111904_bib6","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.bbadis.2012.12.007","article-title":"Strategies for anti-fibrotic therapies","volume":"1832","author":"Rosenbloom","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2019.111904_bib7","doi-asserted-by":"crossref","first-page":"9811","DOI":"10.1021\/acs.jmedchem.8b00294","article-title":"Fibrogenic disorders in human diseases: from inflammation to organ dysfunction","volume":"61","author":"Juillerat-Jeanneret","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111904_bib8","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/jm501562a","article-title":"Nintedanib: from discovery to the clinic","volume":"58","author":"Roth","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111904_bib9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cytogfr.2015.10.002","article-title":"The PDGF system and its antagonists in liver fibrosis","volume":"28","author":"Borkham-Kamphorst","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.ejmech.2019.111904_bib10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.biopha.2017.01.107","article-title":"Sorafenib: a potential therapeutic drug for hepatic fibrosis and its outcomes","volume":"88","author":"Ma","year":"2017","journal-title":"Biomed. Pharma"},{"key":"10.1016\/j.ejmech.2019.111904_bib11","first-page":"525","article-title":"Effect of malotilate on expression of Smads protein in rats with dimenthylnitrosamine-induced hepatic fibrosis","volume":"18","author":"Huang","year":"2015","journal-title":"J.\u00a0Prac. Hepatol"},{"key":"10.1016\/j.ejmech.2019.111904_bib12","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.3324\/haematol.2013.095109","article-title":"Resolution of bone marrow fibrosis in a patient receiving JAK1\/JAK2 inhibitor treatment with ruxolitinib","volume":"98","author":"Wilkins","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.ejmech.2019.111904_bib13","first-page":"4540","article-title":"Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF","volume":"48","author":"Ongenaert","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejmech.2019.111904_bib14","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.cca.2012.07.014","article-title":"Autotaxin in liver fibrosis","volume":"413","author":"Ikeda","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.ejmech.2019.111904_bib15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbior.2012.09.010","article-title":"Structure\u2013function relationships of autotaxin,a secreted lysophospholipase D","volume":"53","author":"Hausmann","year":"2013","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.ejmech.2019.111904_bib16","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.febslet.2014.02.009","article-title":"Autotaxin in the crosshairs: taking aim at cancer and other inflammatory conditions","volume":"588","author":"Benesch","year":"2014","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2019.111904_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(18)30181-4","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiophic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial","volume":"6","author":"Maher","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.ejmech.2019.111904_bib18","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543776.2013.796364","article-title":"Autotaxin inhibitors: a patent review","volume":"23","author":"Barbayianni","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2019.111904_bib19","series-title":"Pyrimidine and Pyridine Derivatives Useful in Therapy","author":"Long","year":"2013"},{"key":"10.1016\/j.ejmech.2019.111904_bib20","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.bmc.2018.02.023","article-title":"Discovery and Optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors","volume":"26","author":"Jing","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111904_bib21","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1021\/jm9000133","article-title":"Halogen bondings-a novel interaction for rational drug design?","volume":"52","author":"Lu","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2019.111904_bib22","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1007\/s00894-013-2005-7","article-title":"A\u00a0knowledge-based halogen bonding scoring function for predicting protein-ligand interactions","volume":"19","author":"Liu","year":"2013","journal-title":"J.\u00a0Mol. Model."},{"key":"10.1016\/j.ejmech.2019.111904_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cbi.2014.12.031","article-title":"Resveratrol inhibits highglucose induced collagen upregulation in cardiac fibroblasts through regulating TGF-\u03b21\u2013Smad3 signaling pathway","volume":"227","author":"Liu","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2019.111904_bib24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jff.2018.05.031","article-title":"The antioxidant and anti-hepatic fibrosis activities of acorns (Quercus liaotungensis) and their natural galloyl triterpenes","volume":"46","author":"Xu","year":"2018","journal-title":"J.\u00a0Funct Foods"},{"key":"10.1016\/j.ejmech.2019.111904_bib25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/01.bor.0000137894.63091.1a","article-title":"Recent advances in fibroblast signaling and biology in scleroderma","volume":"16","author":"Pannu","year":"2004","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.ejmech.2019.111904_bib26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejphar.2016.04.042","article-title":"Isorhamnetin attenuates liver fibrosis by inhibiting TGF-beta\/Smad signaling and relieving oxidative stress","volume":"783","author":"Yang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2019.111904_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.diabres.2017.08.018","article-title":"Transforming growth factor beta (TGF-\u03b2) mediates cardiac fibrosis and induces diabetic cardiomyopathy","volume":"133","author":"Yue","year":"2017","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2019.111904_bib28","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1124\/mol.115.100404","article-title":"Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding","volume":"88","author":"Stein","year":"2015","journal-title":"Mol. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419310566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523419310566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:08:12Z","timestamp":1759327692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523419310566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":28,"alternative-id":["S0223523419310566"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111904","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2019.111904","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111904"}}